Buying Canada-based Clementia is consistent with Ipsen’s strategy to acquire top assets in mid to late stages of development for specialty oncology, neuroscience or rare disease indications, chief commercial officer tells Scrip.
Ipsen is bolstering its portfolio in ultra rare diseases by buying Clementia Pharmaceuticals Inc. of Canada and in so doing reinforcing its strategy of buying first-in-class or best-in-class assets in mid-to-late stage development that offer promising commercial prospects, according to the French pharma's chief commercial officer.
Ipsen is paying $1.04bn up front plus an additional deferred amount of $263m to buy Montreal-based Clementia Pharmaceuticals.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
